91 – 100 of 1515
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
- Contribution to journal › Article
-
Mark
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease
- Contribution to journal › Article
-
Mark
Beware of diffusion models for synthesizing medical images—a comparison with GANs in terms of memorizing brain MRI and chest x-ray images
- Contribution to journal › Article
-
Mark
evoke and evoke+ : design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
- Contribution to journal › Article
-
Mark
Benchmarking Alzheimer’s disease prediction : personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies
- Contribution to journal › Article
-
Mark
IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease
- Contribution to journal › Article
-
Mark
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta
- Contribution to journal › Article
-
Mark
Biofluid biomarkers in distinguishing young-onset dementia from primary psychiatric disorders
- Contribution to journal › Scientific review
-
Mark
Associations of life-course cardiovascular risk factors with late-life cerebral haemodynamics
- Contribution to journal › Article
-
Mark
Plasma p-tau immunoassays in clinical research for Alzheimer's disease
- Contribution to journal › Scientific review
